Results 231 to 240 of about 25,638 (254)

Glucagon-Like Peptide-1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications. [PDF]

Pharmacol Res Perspect
Alharbi NHJ.
europepmc   +1 more source

What Are the Impacts of GLP‐1 Drugs in Patients Needing Head/Neck Surgery?

The Laryngoscope, Volume 136, Issue 10, Page 4110-4111, October 2026.
Chelsea Gelboin‐Burkhart, Liam Gallagher, Bridget Ebert, Samir S. Khariwala   +3 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

Circulation, 2022
Bernard Zinman, Ahmed M Shaman
exaly  

Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis

Pharmacological Research, 2020
Bo Yi, Tian Xia, Cheng Chen
exaly  

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial

Diabetes Care, 2016
Peter G Colman, Bernard Zinman, Chantal Mathieu   +2 more
exaly  

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke: Post Hoc Analysis From the LEADER Trial

Circulation, 2018
Bernard Zinman
exaly  

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

Diabetes Care, 2009
Bernard Zinman, John Buse, Lawrence Blonde   +2 more
exaly  

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial

Circulation, 2018
Bernt J von Scholten, Johannes F E Mann, Vivian Fonseca   +2 more
exaly